www.highlandtherapeutics.com

For Immediate Release:

HIGHLAND THERAPEUTICS ANNOUNCES PUBLICATION IN THE JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

TORONTO, Canada, July 9, 2015—Highland Therapeutics Inc. ("Highland"), a pharmaceutical company, today announced the publication of research findings in the Journal of Child and Adolescent Psychopharmacology ("JCAP").

The publication, "Early Morning Functioning in Stimulant-Treated Children and Adolescents with Attention-Deficit/Hyperactivity Disorder, and its Impact on Caregivers" can be downloaded, in PDF format, at www.highlandtherapeutics.com. It will also be available in a future issue of JCAP's print edition. The research was sponsored by Highland's wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. ("Ironshore").

"We are pleased to have these important findings published in a prestigious, peer-reviewed journal and hope that improved awareness of the issues related to the early morning routine might start a dialogue among physicians and families," said Dr. Randy Sallee, Ironshore's Chief Medical Officer. "Almost 80% of respondents reported discussing early morning functioning (EMF) impairments with the ADHD patient's physician. The results clearly show that more research into this area is needed to help determine what treatment options may more comprehensively address the needs of patients with ADHD."

Dr. Bev Incledon, Ironshore's Senior Vice President, Research & Development, said, "We believe that current stimulant therapies provide inadequate control of ADHD symptoms during the early morning routine, which can have a lasting, negative effect on patients and their families throughout the day. Ironshore's next-generation formulations of methylphenidate (HLD-200) and amphetamine (HLD-100) are being developed specifically to provide patients with a strong start to their day, which we believe can have lasting, *positive* effects. The research findings being published today demonstrate that the prevalence and magnitude of early morning functional impairments might be far greater than what was previously believed."

About Highland Therapeutics Inc.

Highland Therapeutics Inc. is a specialty pharmaceutical company that, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., is leveraging its proprietary technology, DELEXIS®, to optimize the delivery of previously approved drug products. The Company's lead product candidates, HLD-200 and HLD-100, are novel formulations of the psychostimulants (methylphenidate and amphetamine, respectively) used to treat ADHD and are being developed to address a prevalent unmet medical need in the treatment of the disease – inadequate symptom control during the morning routine. Intended for nighttime dosing, DELEXIS® is designed to provide a consistent delay in the initial release of the active drug, followed by a period of extended release; with the objective of providing control of ADHD symptoms immediately upon wakening and throughout the day.

Highland Therapeutics Inc. is a client of MaRS Discovery District's Health Venture Services group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies.

For further information, please visit the Company's website at www.highlandtherapeutics.com, or contact:

Nelson F. Isabel
Chief Financial Officer
(647) 260-7875

Forward-Looking Statements

This press release contains forward-looking information, which reflects Highland's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Highland's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Highland assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.